<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6017B029-89D1-4AF7-96D8-1EB001171821"><gtr:id>6017B029-89D1-4AF7-96D8-1EB001171821</gtr:id><gtr:firstName>Alan John</gtr:firstName><gtr:surname>Knox</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/224F438B-D9C4-4291-9A40-0AEFC75849FC"><gtr:id>224F438B-D9C4-4291-9A40-0AEFC75849FC</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Irving</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D9DFF51-8103-42B7-B910-9735C323F164"><gtr:id>6D9DFF51-8103-42B7-B910-9735C323F164</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B1C99ABD-51A0-4B61-9D3D-1B72EA642ADE"><gtr:id>B1C99ABD-51A0-4B61-9D3D-1B72EA642ADE</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Fogarty</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E8F87A86-72D4-4989-AA3B-D0C29A681D9B"><gtr:id>E8F87A86-72D4-4989-AA3B-D0C29A681D9B</gtr:id><gtr:firstName>Alain</gtr:firstName><gtr:surname>Pitiot</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7EC3E1DE-5F4E-4070-912D-0DF9C387711E"><gtr:id>7EC3E1DE-5F4E-4070-912D-0DF9C387711E</gtr:id><gtr:firstName>Mohammad</gtr:firstName><gtr:surname>Ilyas</gtr:surname><gtr:orcidId>0000-0001-7949-7504</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3B4DAFEF-CDF4-498B-B9DC-5914D96301F4"><gtr:id>3B4DAFEF-CDF4-498B-B9DC-5914D96301F4</gtr:id><gtr:firstName>Gisli</gtr:firstName><gtr:surname>Jenkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EEA89DFC-1EF2-4930-AFE6-9D829B2E9731"><gtr:id>EEA89DFC-1EF2-4930-AFE6-9D829B2E9731</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Thomson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AB1E764B-ADD6-456D-8F2C-1BE31CFEB2E5"><gtr:id>AB1E764B-ADD6-456D-8F2C-1BE31CFEB2E5</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Garibaldi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/102BE0EA-C7A9-4550-BCCD-860D18DA1F52"><gtr:id>102BE0EA-C7A9-4550-BCCD-860D18DA1F52</gtr:id><gtr:firstName>Sally</gtr:firstName><gtr:surname>Chappell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C6BFB9D4-8778-47A7-AB40-B2B661EADA99"><gtr:id>C6BFB9D4-8778-47A7-AB40-B2B661EADA99</gtr:id><gtr:firstName>Guruprasad</gtr:firstName><gtr:otherNames>Padur</gtr:otherNames><gtr:surname>Aithal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN005953%2F1"><gtr:id>AF4C79E3-BFEE-44F7-A9D2-EE473974D607</gtr:id><gtr:title>Nottingham Molecular Pathology Node (NMPN) for Integrated Multi-platform Biomarker Research and Knowledge Transfer</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/N005953/1</gtr:grantReference><gtr:abstractText>The context of the research
There have been substantial recent investments in Stratified Medicine and Analytical Science by the MRC and EPSRC. A recent MRC Pathology Review has highlighted the need for a robust pathway and capability for the development and adoption of new diagnostic tests. Nottingham Molecular Pathology Node will provide the necessary path and capability to fill the needs identified by the MRC review.

Aims and objectives

To create an infrastructure to drive molecular diagnostic biomarker research down the development pathway utilizing molecular pathology/biobanking strengths and integrating computational/bioinformatics expertise
This initiative will bring together Nottingham's expertise in molecular pathology, East midlands Pathology (Empath) which is the largest clinical pathology service in Europe and has the largest repository of archival tissue in Europe, Nottingham Health Sciences Biobank which is the CRC UK National Biobank co-ordinating centre and Nottingham's Advanced data Analysis Centre (ADAC) which has strong computational expertise including bioinformatics, artificial neural networks, statistics and data interpretation skills for integrating knowledge from several platforms. 

To use this infrastructure where Nottingham has existing translational research strengths
Our strategy will be to use the infrastructure to produce world-class innovative research and progress new biomarkers from discovery, down the development pathway into the clinic. Nottingham's major clinical research strengths are: (i) Respiratory and (ii) GI/liver diseases where we have critical mass, expertise, patient cohorts and infrastructure supported by MRC, NIHR, research charities, EU and industry funding. 

To address areas of unmet clinical need 
Chronic Obstructive Pulmonary Disease (COPD) affects over 1 million people in UK and kills 25,000/year. Idiopathic Pulmonary Fibrosis (IPF) is commoner than all leukaemias combined kills 50% within 3 years of diagnosis. Lymphangioleiomyomatosis (LAM) has no effective treatment and we host the UK centre. Cystic Fibrosis (CF), the commonest genetic disease and median age of death is 35-40 usually due to Pseudomonas infection. Hepatitis B/C affect more than 500,000 people in the UK. H. pylori affects 1 in 6 people in the UK and causes peptic ulceration and gastric cancer.

To use existing large patient cohorts to facilitate translation
Nottingham Respiratory Research Unit (NRRU) has well-phenotyped cohorts (n) including IPF (550), LAM (100), CF (400), and COPD (400). We contribute to national/international collaborations including IMI UBIOPRED, MRCMAP COPD, NIHR Respiratory TRP, MRC Rare Diseases Consortium, CRAFT Consortium. The NIHR Nottingham Digestive Disease Biomedical Research Unit (NDDBRU) hosts HCV Research UK, a national cohort (10,000) and clinical database/biorepository, and is a MRC Stratified Medicine Consortium STOP-HCV member. NDDBRU has non-alcoholic fatty liver disease (NAFLD; 300), compensated cirrhosis (200), Hepatitis B (200) and H.pylori cohorts. 

To use the infrastructure to train the next generation of molecular pathologists
We will run high quality Master' levels programmes, short taught courses and summer training schools meeting NHS/industry needs for molecular pathologists in the genomic medicine era. NMPN will provide a platform for aligning ACL posts, PhDs and MSc projects.

Potential applications and benefits
Our approach will develop world leading translational molecular diagnostic capabilities in GI/liver and respiratory diseases. The work will lead to the development and clinical application of biomarkers/molecular diagnostics and computer modeling algorithms in several important infective, inflammatory and fibrotic diseases of the respiratory, GI systems and liver and will likely be applicable to diseases in other organ systems. It will benefit patients, scientists, industrial partners and the health and wealth of the nation.</gtr:abstractText><gtr:technicalSummary>NMPN brings together pathologists, molecular biologists, clinicians, computer scientists, the Nottingham Health Science Biobank (NHSB), Nottingham University Hospitals NHS Trust (NUH), Empath, Pharma/biotech companies and electronic engineering companies. 
Co-localisation of expertise, an exceptional tissue repository with linked real-time stratified patient data and well-defined clinical cohorts are resources we aim to use to create a new and original infrastructure encompassing informatics, computational modelling and molecular pathology. This will allow (i) biomarker testing to reveal hidden disease strata (discovery push), (ii) testing clinically stratified patient cohorts to reveal discriminatory biomarkers (clinical pull) and (iii) robust biomarker validation enabling early clinical translation. NMPN models will integrate multi-platform data including DNA/RNA/Proteomic/Metabolomic profiles, digital image analysis, genomic profiling of pathogens as well as data from other sources (e.g. radiology) to provide clinical decision support. 
Our models will be tested in infection/inflammation/fibrosis and repair - disease processes with variable outcomes and treatment responses and providing an ideal template for stratification. NMPN will focus on upper &amp;amp; lower gastrointestinal tract, liver and respiratory tract, which feature amongst Nottingham's major research strengths. Although developed for infection/inflammation/fibrosis the models will be transferable to other diseases and easily disseminated to other nodes. 
We will work closely with industry and align with other nodes to transfer knowledge and ensure research is translated from bench-to-bedside. NMPN will provide in-depth training for PhD students, new Fellowships in Molecular Pathology, rotation of NHS clinical pathology trainees through the Node, and creation of a new Associate Professor post. We will deliver a distance-learning MSc course for the network and organise annual summer training schools.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit?
1. Patients and the public
2. Respiratory and GI/Liver translational researchers
3. Discovery Scientists
4. The wider scientific community
5. Pharmaceutical and diagnostics companies
6. Other molecular pathology nodes
7. Government and policymakers

How will they benefit?
Patients and the public: This proposal is aimed at developing new molecular diagnostics/biomarkers for stratifying a number of important diseases with a view to allowing appropriate targeting with existing or novel therapies. This will help ensure that in future patients are treated with the right drug for their condition at the most appropriate time and there will be suitable biomarkers to evaluate the response to treatment. In the medium to long term this is likely to improve the quality of life and longevity of patients with a number of conditions, which currently have high morbidity and mortality. There is therefore a real possibility of a major impact on the nation's health.

Respiratory and GI/Liver researchers: The areas of disease we are researching are those that there is a real need to develop biomarkers of infection, biomarkers predicting decline and the appropriate point to intervene with different therapies. Our results are likely to have wide recognition within the respective scientific communities.

Discovery scientists: The node will provide a vehicle for the translation of excellent basic discovery research making sure that cutting edge discovery science is not wasted and is able to reap its full benefit.

The wider scientific community: Although our node will focus on respiratory, GI and liver diseases the platform created could be used to facilitate research in diseases in other organs as the techniques developed, knowledge of disease mechanisms and modeling algorithms developed may be applicable to a much wider range of infective, inflammatory and fibrotic diseases. 

Pharmaceutical and diagnostics companies: Pharmaceutical companies interested in drug development will benefit from developing stratified models and companion diagnostic which indicate the phenotypes of patient that their products can best target. The route to market will be more rapid and the chance of test and drug adoption into routine clinical practice will be considerably enhanced.

Other molecular pathology nodes: The platforms, techniques and modeling algorithms we set up will be shared with other molecular pathology nodes in the network giving added value to their work. This is likely to be a twoway exchange of knowledge in an ongoing manner. By integrating the training components with training taking place in the other nodes we will ensure that the UK has one of the most comprehensive training structures for molecular pathology worldwide.

Government and policymakers: By setting up a series of molecular pathology nodes this initiative will give the UK an international lead and is increase its competitiveness as a marketplace for new molecular diagnostic and biomarker research. It will also improve flow from outside of the UK into the UK of trainees capitalizing on excellent training opportunities MSc and PhD's in molecular pathology. It is likely therefore to contribute to the nations wealth. It will provide data on new ways of stratifying the phenotypes of patients with disease which will be helpful to organisations such as NICE when developing guidelines for disease treatment and monitoring.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2422633</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>IGNITE event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>05B05CDB-6EBB-4EB9-B39F-17EFD137E826</gtr:id><gtr:impact>Day of interactive events to educate public</gtr:impact><gtr:outcomeId>58bd923a946e12.19113222</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mayfest University of Nottingham</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E9B6FEBE-0A9C-4702-9249-558F2ADA6AE5</gtr:id><gtr:impact>Open day where research presented</gtr:impact><gtr:outcomeId>56cc42a9e57a88.79516739</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>830BC092-F4E3-458A-B256-AB93F75BE520</gtr:id><gtr:title>Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca4134405bb0460499e67f59fdc67d06"><gtr:id>ca4134405bb0460499e67f59fdc67d06</gtr:id><gtr:otherNames>Allen RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a8589ff836a09.17934392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DB72ADA-E141-461F-A27F-467367328281</gtr:id><gtr:title>Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa56070c948c0fb966fe86c46b8bd5f7"><gtr:id>aa56070c948c0fb966fe86c46b8bd5f7</gtr:id><gtr:otherNames>Foster GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a85892ba72b59.59425837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F491E4A1-5A6D-4D7A-B32B-92851E1C45DC</gtr:id><gtr:title>Reply to: &amp;quot;Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cc1a629d431ece4a70f4e2339867e5a"><gtr:id>4cc1a629d431ece4a70f4e2339867e5a</gtr:id><gtr:otherNames>da Silva Filipe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a858928d36ff2.52923689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A22CEA-B8DA-42F7-BDDD-5181A19B093A</gtr:id><gtr:title>The differential effects of azithromycin on the airway epithelium in&amp;nbsp;vitro and in&amp;nbsp;vivo.</gtr:title><gtr:parentPublicationTitle>Physiological reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ca1bb9b22d2fea9c6ebc9f2506fb969"><gtr:id>7ca1bb9b22d2fea9c6ebc9f2506fb969</gtr:id><gtr:otherNames>Slater M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2051-817X</gtr:issn><gtr:outcomeId>58bd7ecd73f7b8.14001889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A78CFB74-D44B-4C63-9705-05F3E6E361DF</gtr:id><gtr:title>Epigenetic dysregulation of interleukin 8 (CXCL8) hypersecretion in cystic fibrosis airway epithelial cells.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d2560aa032efab7ec8312ae4efafe7"><gtr:id>69d2560aa032efab7ec8312ae4efafe7</gtr:id><gtr:otherNames>Poghosyan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>58bd7def9bb3a8.95786118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1EA574C-974D-4FB1-B862-E268D5A91A48</gtr:id><gtr:title>Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis.</gtr:title><gtr:parentPublicationTitle>Annals of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73664167edb8671dbdd30ee9d535432a"><gtr:id>73664167edb8671dbdd30ee9d535432a</gtr:id><gtr:otherNames>Hurley MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2325-6621</gtr:issn><gtr:outcomeId>5a858c2c4e74c9.61325565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B5A3BA6-BB2C-4012-BBB0-8830758EAD71</gtr:id><gtr:title>Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/031e8211fc8451e560e2a1dbd79f1b13"><gtr:id>031e8211fc8451e560e2a1dbd79f1b13</gtr:id><gtr:otherNames>West J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>5a8587f2d200d6.12574316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4A3FB10-1CB2-4AA7-8304-6DCB61E5C41C</gtr:id><gtr:title>Evaluation of the PPAR-? Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e1680defc952f1d62463433d014684b"><gtr:id>8e1680defc952f1d62463433d014684b</gtr:id><gtr:otherNames>Anderson JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58bd7ece366536.78461847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DDC8A2E-6710-48EE-B723-CE45E3B7D075</gtr:id><gtr:title>Demand for CT scans increases during transition from paediatric to adult care: an observational study from 2009 to 2015.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f53664949540a1eebfb91070dcb4dc72"><gtr:id>f53664949540a1eebfb91070dcb4dc72</gtr:id><gtr:otherNames>Thurley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>5a858c2cbd2476.79909008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>910BEDA8-AE2C-4D8A-8222-CF7068769D47</gtr:id><gtr:title>Cathepsin K in Lymphangioleiomyomatosis: LAM Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800a3f9b48ed142736d1380e2678afbc"><gtr:id>800a3f9b48ed142736d1380e2678afbc</gtr:id><gtr:otherNames>Dongre A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5a858aad1e9037.63757280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA4FDE16-A84A-420B-A1BC-36C7A4DBC7BD</gtr:id><gtr:title>Helicobacter pylori-Mediated Protection from Allergy Is Associated with IL-10-Secreting Peripheral Blood Regulatory T Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea1cb54c2e2cfa0bee51e680fe1e2dcf"><gtr:id>ea1cb54c2e2cfa0bee51e680fe1e2dcf</gtr:id><gtr:otherNames>Hussain K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a858bc71bde29.46187740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A021BE2A-0E34-4CFA-A8F8-155EC950DC9F</gtr:id><gtr:title>Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b96bbd90f992b4425d670a930c7297"><gtr:id>a8b96bbd90f992b4425d670a930c7297</gtr:id><gtr:otherNames>Bee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a858aad90ab46.64977699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB9D8AA3-0C9A-4BC6-8DBD-16CDFA2550EC</gtr:id><gtr:title>Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10797830581bf2468443470e78d130a7"><gtr:id>10797830581bf2468443470e78d130a7</gtr:id><gtr:otherNames>Roberts K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a85892b2a3a31.73795715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DF9C725-66D7-4CA0-A3DD-4B3CEC7D7552</gtr:id><gtr:title>Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbb6c2dbdbbbb0453b95e990fc58eae7"><gtr:id>bbb6c2dbdbbbb0453b95e990fc58eae7</gtr:id><gtr:otherNames>Thomas JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>5a8587f2522411.24409913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FA6E170-61F2-4A73-8077-476E1F120FCF</gtr:id><gtr:title>Modeling and control of operator functional state in a unified framework of fuzzy inference petri nets.</gtr:title><gtr:parentPublicationTitle>Computer methods and programs in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5dc76b202722e659924df75046b1c95d"><gtr:id>5dc76b202722e659924df75046b1c95d</gtr:id><gtr:otherNames>Zhang JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0169-2607</gtr:issn><gtr:outcomeId>5a858855e3a196.49429279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BDE3E69-8912-41FF-B567-4D9FAC5F2470</gtr:id><gtr:title>Effect of Helicobacter pylori infection on growth trajectories in young Ethiopian children: a longitudinal study.</gtr:title><gtr:parentPublicationTitle>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4109f4e91688860820cbd120b7fe4e0b"><gtr:id>4109f4e91688860820cbd120b7fe4e0b</gtr:id><gtr:otherNames>Taye B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1201-9712</gtr:issn><gtr:outcomeId>5a858c7c965de0.94355620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6F30B6F-0E4B-4814-997E-4E5F520B4D1B</gtr:id><gtr:title>Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f4736589f4d300b8fcd84212396e994"><gtr:id>0f4736589f4d300b8fcd84212396e994</gtr:id><gtr:otherNames>Jenkins RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a858a004890c7.56503083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6832C15-40F6-401E-9301-6539297E3C82</gtr:id><gtr:title>A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5550e980e8e08dcf14ac182f15730679"><gtr:id>5550e980e8e08dcf14ac182f15730679</gtr:id><gtr:otherNames>Friedman SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a8587f0bfe4a8.35150740</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5834605-1E42-485D-AC9E-A01C32655D9D</gtr:id><gtr:title>Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cc1a629d431ece4a70f4e2339867e5a"><gtr:id>4cc1a629d431ece4a70f4e2339867e5a</gtr:id><gtr:otherNames>da Silva Filipe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a8589297688f6.30082726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F61ABBAD-C340-42DB-987D-63DDB1EB8B13</gtr:id><gtr:title>Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d8b063eaeee70d4bfde640650408a2"><gtr:id>70d8b063eaeee70d4bfde640650408a2</gtr:id><gtr:otherNames>Green AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>58bd93f1e4ad97.99923689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFFA5466-5910-47D4-B860-1F8D8FAF5F4F</gtr:id><gtr:title>Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>Journal of hepatocellular carcinoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/505797ac4f7609477cd9268909351a9b"><gtr:id>505797ac4f7609477cd9268909351a9b</gtr:id><gtr:otherNames>Fateen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2253-5969</gtr:issn><gtr:outcomeId>5a8587f0519144.65485778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8AEB8A3-2036-4D8E-8330-BCD7C1279A7F</gtr:id><gtr:title>Semi-Supervised Fuzzy Clustering with Feature Discrimination.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cd97b4a1e149c4f95df16a9cd3b6324"><gtr:id>0cd97b4a1e149c4f95df16a9cd3b6324</gtr:id><gtr:otherNames>Li L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58bd93f3708f00.69521349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>882DB27F-7939-491B-85FB-F30AD1E4AC64</gtr:id><gtr:title>An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b5e216fa7a4c270fb0472360284ec9"><gtr:id>47b5e216fa7a4c270fb0472360284ec9</gtr:id><gtr:otherNames>Maher TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5a8589fd785d58.74560075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D029B626-0594-40BD-9A84-15BCA4DDF461</gtr:id><gtr:title>Automatic detection of protected health information from clinic narratives.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1532-0464</gtr:issn><gtr:outcomeId>58bd93f3415091.34248998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C748883-B753-456D-9998-5DF1E167C8EF</gtr:id><gtr:title>Atomic Resolution Structures of Human Bufaviruses Determined by Cryo-Electron Microscopy.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ecdcc9a75efe61569ae89d2cdabfc84"><gtr:id>2ecdcc9a75efe61569ae89d2cdabfc84</gtr:id><gtr:otherNames>Ilyas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>5a85871256a752.02855960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1D29C5B-53A1-493E-8B24-E4EE9D436462</gtr:id><gtr:title>Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da255050404c975334359f21f4f0cb44"><gtr:id>da255050404c975334359f21f4f0cb44</gtr:id><gtr:otherNames>Harris M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>5a858928ace610.98648910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>159DF6C3-AD85-4E57-98EE-F274F375308F</gtr:id><gtr:title>Role of Rho-Associated Coiled-Coil Forming Kinase Isoforms in Regulation of Stiffness-Induced Myofibroblast Differentiation in Lung Fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24f2e8d574d925871066e5b5855dea20"><gtr:id>24f2e8d574d925871066e5b5855dea20</gtr:id><gtr:otherNames>Htwe SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>58bd7e3d6e5199.54395790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2953958-4AE8-4EA3-BA1E-620C7104ED31</gtr:id><gtr:title>Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d582accefa04f804d6bab230d9dd36e"><gtr:id>5d582accefa04f804d6bab230d9dd36e</gtr:id><gtr:otherNames>Martin NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a85892b828ee1.30965876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65D29F58-96F1-4E08-B90B-DAF31FE85B41</gtr:id><gtr:title>An Epithelial Integrin Regulates the Amplitude of Protective Lung Interferon Responses against Multiple Respiratory Pathogens.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc5bef4b062f2cdb9692530a4cf168d5"><gtr:id>cc5bef4b062f2cdb9692530a4cf168d5</gtr:id><gtr:otherNames>Meliopoulos VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5a8589ffad8394.54965558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4248E352-7826-48CE-AFBE-47B43EDF4B46</gtr:id><gtr:title>Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.</gtr:title><gtr:parentPublicationTitle>The journal of pathology. Clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d8b063eaeee70d4bfde640650408a2"><gtr:id>70d8b063eaeee70d4bfde640650408a2</gtr:id><gtr:otherNames>Green AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-4538</gtr:issn><gtr:outcomeId>58bd93f2172592.44915307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C40DA87E-045D-4C81-B545-13C11DD40977</gtr:id><gtr:title>Cten promotes epithelial-mesenchymal transition through the post-transcriptional stabilization of Snail.</gtr:title><gtr:parentPublicationTitle>Molecular carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36ecb202f2a71578643540dadcb41987"><gtr:id>36ecb202f2a71578643540dadcb41987</gtr:id><gtr:otherNames>Thorpe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0899-1987</gtr:issn><gtr:outcomeId>5a858713304702.92164904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABA9715B-6E4B-4C15-9744-EBD48F1203EF</gtr:id><gtr:title>Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae76c1192e8b231849c103152bb8c919"><gtr:id>ae76c1192e8b231849c103152bb8c919</gtr:id><gtr:otherNames>Harris R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a8587f27e7f29.57704274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>191934E0-9E4D-41F2-AB0A-B05FE9004B48</gtr:id><gtr:title>Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d1f0db10b035221717824f6472168d"><gtr:id>87d1f0db10b035221717824f6472168d</gtr:id><gtr:otherNames>Eslam M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a85892af13871.73311940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DDE52B2-4616-40E5-9293-37E41ED16DE2</gtr:id><gtr:title>Erratum to: Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70d8b063eaeee70d4bfde640650408a2"><gtr:id>70d8b063eaeee70d4bfde640650408a2</gtr:id><gtr:otherNames>Green AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>5a858856472dd4.46265982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5DB8928-224D-4DF0-9E8B-62D43A8A459C</gtr:id><gtr:title>Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.</gtr:title><gtr:parentPublicationTitle>Alcohol (Fayetteville, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd65b7cb9b04d90406706c2e48650ee"><gtr:id>2bd65b7cb9b04d90406706c2e48650ee</gtr:id><gtr:otherNames>Whitfield JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0741-8329</gtr:issn><gtr:outcomeId>5a8587efd92557.61853203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A38D6F12-F7ED-4942-8978-5221CCADDC44</gtr:id><gtr:title>Association of Liver Injury From Specific Drugs, or Groups of&amp;nbsp;Drugs, With Polymorphisms in HLA and Other Genes in a&amp;nbsp;Genome-Wide Association Study.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed7acf250e8f1e7c8da50ba61e9860ed"><gtr:id>ed7acf250e8f1e7c8da50ba61e9860ed</gtr:id><gtr:otherNames>Nicoletti P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>58bd9376f3d478.44928031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A241BA6-7AC4-4634-87B6-299D040C0D46</gtr:id><gtr:title>Reply to: Treatment of Pulmonary Lymphangioleiomyomatosis During Pregnancy.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8daaabf2c4782bef479bb7d8bf61ec29"><gtr:id>8daaabf2c4782bef479bb7d8bf61ec29</gtr:id><gtr:otherNames>Gupta N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a858aac735686.23127101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0385D2D-8A2C-4CC8-A6E4-0B80AF247246</gtr:id><gtr:title>Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d992a2a4f63bf79792f094bfaa32a4cd"><gtr:id>d992a2a4f63bf79792f094bfaa32a4cd</gtr:id><gtr:otherNames>Agrawal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0036-5521</gtr:issn><gtr:outcomeId>58bd9376924646.68077058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>758185C9-49B7-4A8E-9DE9-E7835774E2E5</gtr:id><gtr:title>Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey.</gtr:title><gtr:parentPublicationTitle>Frontline gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-4137</gtr:issn><gtr:outcomeId>5a8587f12871b3.82674390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C8E484B-B11A-4E1B-8683-1B4AECC184FC</gtr:id><gtr:title>The Human Stomach in Health and Disease: Infection Strategies by Helicobacter pylori.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8daea59cb2444c40ecae21e2ae9d204b"><gtr:id>8daea59cb2444c40ecae21e2ae9d204b</gtr:id><gtr:otherNames>Robinson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>5a858c7c6ba881.09270011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78A4DDEC-0B80-4A02-A395-3B8DA00A2DBB</gtr:id><gtr:title>Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders.</gtr:title><gtr:parentPublicationTitle>Clinical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dad4f9827acf94315f08ad19ab0c1f6"><gtr:id>1dad4f9827acf94315f08ad19ab0c1f6</gtr:id><gtr:otherNames>Kristensen JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9120</gtr:issn><gtr:outcomeId>56e0041939cc27.70673748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>503232D4-1E4A-4A0C-A0F0-E665002608D9</gtr:id><gtr:title>Facile Surfactant-Free Synthesis of p-Type SnSe Nanoplates with Exceptional Thermoelectric Power Factors.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c23eb60014d7f25b1707d8841669c186"><gtr:id>c23eb60014d7f25b1707d8841669c186</gtr:id><gtr:otherNames>Han G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58bd7ecd488275.45297166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A29737-FD10-4C6C-A2E6-F9976A280C5F</gtr:id><gtr:title>A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/074173c0a663433a9cee5753743a937d"><gtr:id>074173c0a663433a9cee5753743a937d</gtr:id><gtr:otherNames>Urbanowicz RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a85892c644923.21996021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E1653EB-AD20-470C-9CD6-6D3169CE1C6A</gtr:id><gtr:title>Helicobacter pylori vacA transcription is genetically-determined and stratifies the level of human gastric inflammation and atrophy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92cf6259609c8a92f9b51be98ebb3417"><gtr:id>92cf6259609c8a92f9b51be98ebb3417</gtr:id><gtr:otherNames>Sinnett CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>5a858bc6b75e56.64942164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29460D73-E325-4451-ABBC-9A7D3B164C8C</gtr:id><gtr:title>Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study.</gtr:title><gtr:parentPublicationTitle>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23b9c5419a85a979b92dec326c3c7d53"><gtr:id>23b9c5419a85a979b92dec326c3c7d53</gtr:id><gtr:otherNames>Barr HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1569-1993</gtr:issn><gtr:outcomeId>58bd7ece0aa5e7.42854773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C20D8B5-B127-4790-A8F4-BB7858F3D55F</gtr:id><gtr:title>Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0507eb253ebfe9054da0e4745b069a4e"><gtr:id>0507eb253ebfe9054da0e4745b069a4e</gtr:id><gtr:otherNames>Harman DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>5a8587f009e5c1.36923030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F7ED6BB-4B00-4477-A0C3-7FB37FFF6F41</gtr:id><gtr:title>MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f99ab5af6dcd53ff7cc40005ff0733"><gtr:id>64f99ab5af6dcd53ff7cc40005ff0733</gtr:id><gtr:otherNames>Thabet K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a85892a9471c7.67735543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AD59045-F06E-4226-954A-3F6476D56DEC</gtr:id><gtr:title>Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aea99357b5fd1880435533ac4c8d42b7"><gtr:id>aea99357b5fd1880435533ac4c8d42b7</gtr:id><gtr:otherNames>Naveed SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a858aadb4f5b6.13872676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07CADD20-5A75-4250-8C24-524A0D9C14F4</gtr:id><gtr:title>Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37c5fa42eb481ff532a0d799aafab95f"><gtr:id>37c5fa42eb481ff532a0d799aafab95f</gtr:id><gtr:otherNames>Cane JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>56e004187825f3.23729652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F974E66-647F-4782-84BE-805D57055F89</gtr:id><gtr:title>HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e23a5af41938865cdf70b701b89bdb7d"><gtr:id>e23a5af41938865cdf70b701b89bdb7d</gtr:id><gtr:otherNames>Wong NACS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>5a8587121d1885.03639704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD07EC75-4668-4A3C-BC4E-44BC6C6E0F76</gtr:id><gtr:title>&amp;quot;Squirrel&amp;quot; Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments.</gtr:title><gtr:parentPublicationTitle>Journal of biomolecular techniques : JBT</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56347a58fef6daec35e63fd903d9e928"><gtr:id>56347a58fef6daec35e63fd903d9e928</gtr:id><gtr:otherNames>Ebili HO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1524-0215</gtr:issn><gtr:outcomeId>5a8587137df731.73148111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D437D4D-5B30-4752-9876-44E9F067B916</gtr:id><gtr:title>Statistical colour models: an automated digital image analysis method for quantification of histological biomarkers.</gtr:title><gtr:parentPublicationTitle>Biomedical engineering online</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a6c96c5826d9d091908263fa1f740c4"><gtr:id>4a6c96c5826d9d091908263fa1f740c4</gtr:id><gtr:otherNames>Shu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-925X</gtr:issn><gtr:outcomeId>58bd94d9353d27.68220369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C150D4AA-99ED-4465-A781-F710C65A3C67</gtr:id><gtr:title>A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.</gtr:title><gtr:parentPublicationTitle>Pharmacological research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbdd8d23ec658f39ddcc4fbe4d6fe83f"><gtr:id>dbdd8d23ec658f39ddcc4fbe4d6fe83f</gtr:id><gtr:otherNames>Todd I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1043-6618</gtr:issn><gtr:outcomeId>5a858855b0e849.50485119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C0AC955-ADC1-4AB8-9FEF-37124573B501</gtr:id><gtr:title>Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7357241b5cb5630d9a88baeae0a9c85f"><gtr:id>7357241b5cb5630d9a88baeae0a9c85f</gtr:id><gtr:otherNames>McCormack FX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a858aaca38ec9.12842327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B3836EB-C436-4A31-B2F1-4BD0C7DFF444</gtr:id><gtr:title>To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f4736589f4d300b8fcd84212396e994"><gtr:id>0f4736589f4d300b8fcd84212396e994</gtr:id><gtr:otherNames>Jenkins RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a8589ffd92c28.27061719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9760B2E0-F7AB-4DE4-8281-0DC8D1569C3E</gtr:id><gtr:title>The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience.</gtr:title><gtr:parentPublicationTitle>Epidemiology and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6690bf3b66da0793face71500fec10e6"><gtr:id>6690bf3b66da0793face71500fec10e6</gtr:id><gtr:otherNames>Hussein NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-2688</gtr:issn><gtr:outcomeId>5a85892b5577f5.52629858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06A67F0A-CC57-4022-855A-C651DA3778D1</gtr:id><gtr:title>Accelerated extracellular matrix turnover during exacerbations of COPD.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f13c25b6d4ef7faecebaab25a3792e"><gtr:id>76f13c25b6d4ef7faecebaab25a3792e</gtr:id><gtr:otherNames>Sand JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>56e00419a1d179.17741363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9977212A-0422-4FEE-AE0F-99D87C158ABD</gtr:id><gtr:title>The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd9dc19f58376ec7ea99cac38db7a810"><gtr:id>dd9dc19f58376ec7ea99cac38db7a810</gtr:id><gtr:otherNames>Young J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>5a85892a6cc982.68501594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49FC303A-36A8-48DB-853B-4B8130A3E694</gtr:id><gtr:title>Correction for Ferreira et al., A Novel Method for Genotyping the Helicobacter pylori vacA Intermediate Region Directly in Gastric Biopsy Specimens.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/191d297ba188e8bfdf95231b1c512b82"><gtr:id>191d297ba188e8bfdf95231b1c512b82</gtr:id><gtr:otherNames>Ferreira RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>5a858bc6e60da8.59763087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3852B792-99D9-410B-8119-8C64682047B0</gtr:id><gtr:title>Loss of epithelial Gq and G11 signaling inhibits TGF? production but promotes IL-33-mediated macrophage polarization and emphysema.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cc10d22d69f590782e2539a923e5cc7"><gtr:id>2cc10d22d69f590782e2539a923e5cc7</gtr:id><gtr:otherNames>John AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>58bd7ecdca9b95.24655220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B0BE22F-2D57-4261-9C32-89350CA6E065</gtr:id><gtr:title>HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed7acf250e8f1e7c8da50ba61e9860ed"><gtr:id>ed7acf250e8f1e7c8da50ba61e9860ed</gtr:id><gtr:otherNames>Nicoletti P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>58bd9376c4adb6.80758763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7AB97BA-3BD9-421C-82F2-5DDB6946B066</gtr:id><gtr:title>A hybrid model for automatic identification of risk factors for heart disease.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1532-0464</gtr:issn><gtr:outcomeId>58bd93f26c1615.63198074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4778DB8D-22AF-4395-8B18-BF3C6CA3022D</gtr:id><gtr:title>sTREM-1 is elevated in cystic fibrosis and correlates with proteases.</gtr:title><gtr:parentPublicationTitle>Pediatric pulmonology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85fd0f1c1c246a23aae86fd5d509c86c"><gtr:id>85fd0f1c1c246a23aae86fd5d509c86c</gtr:id><gtr:otherNames>Forrester DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1099-0496</gtr:issn><gtr:outcomeId>58bd7e3d907f15.77808982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3BD1B9A-CAA0-4361-8C5C-6E47FC526210</gtr:id><gtr:title>FibroGENE: A gene-based model for staging liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d1f0db10b035221717824f6472168d"><gtr:id>87d1f0db10b035221717824f6472168d</gtr:id><gtr:otherNames>Eslam M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a85892c162c81.78818680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DE5E3FF-86D0-4B0A-8757-80E529D2E464</gtr:id><gtr:title>Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017.</gtr:title><gtr:parentPublicationTitle>Endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e74d153b1142762d03807f1b2e4f34e"><gtr:id>3e74d153b1142762d03807f1b2e4f34e</gtr:id><gtr:otherNames>Dumonceau JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0013-726X</gtr:issn><gtr:outcomeId>5a8587f1eb9268.54656060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F0372CC-9E56-4069-AB5C-9038E8537775</gtr:id><gtr:title>The influence of adiposity and acute exercise on circulating hepatokines in normal weight and overweight/obese men.</gtr:title><gtr:parentPublicationTitle>Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa75d5aa1d94062190e0150a6c00be5b"><gtr:id>aa75d5aa1d94062190e0150a6c00be5b</gtr:id><gtr:otherNames>Sargeant JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1715-5312</gtr:issn><gtr:outcomeId>5a8587f09b1468.45146442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>150899C8-0CE3-4994-9916-752183CC8C8E</gtr:id><gtr:title>Association between infection with Helicobacter pylori and atopy in young Ethiopian children: A longitudinal study.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4109f4e91688860820cbd120b7fe4e0b"><gtr:id>4109f4e91688860820cbd120b7fe4e0b</gtr:id><gtr:otherNames>Taye B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>5a858c2ce35266.50298548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>413D4B75-901F-48B1-8535-CA8A3D4EE608</gtr:id><gtr:title>Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/640066d44c0c0ff681f127fcc480dff3"><gtr:id>640066d44c0c0ff681f127fcc480dff3</gtr:id><gtr:otherNames>Cheung MCM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a85892acc09a3.64713285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78EA469F-D060-4B8F-9EB0-D71701ED7A80</gtr:id><gtr:title>HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e38b3e2a48a194c09fad87d32efc2dea"><gtr:id>e38b3e2a48a194c09fad87d32efc2dea</gtr:id><gtr:otherNames>Qaiser T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>5a8587128921b7.37699982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D821B87-A43A-47C9-814D-15F43C9A2801</gtr:id><gtr:title>Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.</gtr:title><gtr:parentPublicationTitle>Antiviral chemistry &amp; chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a085e48d75abbd8448c521eafb7788b"><gtr:id>8a085e48d75abbd8448c521eafb7788b</gtr:id><gtr:otherNames>Baloch K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0956-3202</gtr:issn><gtr:outcomeId>5a85892a47a146.01975244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D62FBF5B-3FE8-4841-B22E-E609F513AE3A</gtr:id><gtr:title>IFN-?3, not IFN-?4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d1f0db10b035221717824f6472168d"><gtr:id>87d1f0db10b035221717824f6472168d</gtr:id><gtr:otherNames>Eslam M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a85892a137cf2.57329334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B128C7-F5FA-4702-B967-84089A003F7C</gtr:id><gtr:title>Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0944-1174</gtr:issn><gtr:outcomeId>5a8587f02ebf83.70683314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C93377A9-4728-47F0-A1F4-02EE2D1D1166</gtr:id><gtr:title>Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00cf2a91b39513964aeafe7512573b9e"><gtr:id>00cf2a91b39513964aeafe7512573b9e</gtr:id><gtr:otherNames>Padam P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>5a85892c3ab477.15527093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A50ABC59-B70E-40E5-934F-1F362B506797</gtr:id><gtr:title>Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fca7185e99dfbeff7a4f920806ececc"><gtr:id>3fca7185e99dfbeff7a4f920806ececc</gtr:id><gtr:otherNames>Hudson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn><gtr:outcomeId>5a858929a7d0f1.99447851</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B1CDE1E-A718-4939-9C26-46C4427FE153</gtr:id><gtr:title>Dynamics of 5-carboxylcytosine during hepatic differentiation: Potential general role for active demethylation by DNA repair in lineage specification.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d680519a3640e90be46ebbb7fa2e5943"><gtr:id>d680519a3640e90be46ebbb7fa2e5943</gtr:id><gtr:otherNames>Lewis LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn><gtr:outcomeId>5a8587f2b06806.70895463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A26D5F-6FF8-498A-9DB7-BB0F6A04BE68</gtr:id><gtr:title>Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/960ac85c78f1ca8777bf94563b2f3914"><gtr:id>960ac85c78f1ca8777bf94563b2f3914</gtr:id><gtr:otherNames>Baldry EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5a8587f0ebc039.15604645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD638861-9D50-4C80-B58D-6595C2B83BD2</gtr:id><gtr:title>MDM2 Expression in the Progression of Barrett's Oesophagus.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04a0a8da3813515e96fa3681efaa0ed4"><gtr:id>04a0a8da3813515e96fa3681efaa0ed4</gtr:id><gtr:otherNames>Robinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>5a858712b91b90.93024112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BAB3B1A-3846-475F-A788-2EF550A6C9BA</gtr:id><gtr:title>An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ac09768df969578d94e2df3c67c073a"><gtr:id>6ac09768df969578d94e2df3c67c073a</gtr:id><gtr:otherNames>White ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a858a000a8323.42424541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>632488D7-4908-4E41-8D88-737276E38AA6</gtr:id><gtr:title>Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23b9c5419a85a979b92dec326c3c7d53"><gtr:id>23b9c5419a85a979b92dec326c3c7d53</gtr:id><gtr:otherNames>Barr HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>56e0041a02a578.60606359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A07962A-642F-4AFF-868B-AE7FECC77D34</gtr:id><gtr:title>Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin av?6 Expression.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e67733947b6575b2cc2073f08995211"><gtr:id>6e67733947b6575b2cc2073f08995211</gtr:id><gtr:otherNames>Tatler AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56e0029b5b19d8.21395064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0300534-0768-45AC-8A86-D23760ADBD5D</gtr:id><gtr:title>Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd89e08bfb4c7846101701582e9c34f6"><gtr:id>bd89e08bfb4c7846101701582e9c34f6</gtr:id><gtr:otherNames>Urban TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a8587f158c366.55492907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49A2E9E-ADFC-4D60-BB29-DDFF5DB577D3</gtr:id><gtr:title>KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2da70fb233545f5d21290937e1e3df23"><gtr:id>2da70fb233545f5d21290937e1e3df23</gtr:id><gtr:otherNames>Green WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58bd93f1b5b850.99448411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D595C02-E829-4773-8C37-AC8833A64A35</gtr:id><gtr:title>Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b5471bcd8d3be018026c072b85dae24"><gtr:id>6b5471bcd8d3be018026c072b85dae24</gtr:id><gtr:otherNames>Kaewkangsadan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>5a858712e77ce8.95936961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE16F307-1782-40C1-93F2-F0422DA1634A</gtr:id><gtr:title>Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>5a8589290b1ab4.10805660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CED0CBD7-13D9-4BAF-81AA-415D555DEC30</gtr:id><gtr:title>Spontaneous central venous thrombosis and shunt occlusion following peritoneovenous shunt placement for intractable ascites.</gtr:title><gtr:parentPublicationTitle>Annals of the Royal College of Surgeons of England</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bab5c09eab8e7c2102b2702b6693e7e"><gtr:id>0bab5c09eab8e7c2102b2702b6693e7e</gtr:id><gtr:otherNames>Hariharan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0035-8843</gtr:issn><gtr:outcomeId>5a8587f2300de8.54461182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>701705CE-F68C-4EAD-8680-B2D48C8DC93D</gtr:id><gtr:title>Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8daaabf2c4782bef479bb7d8bf61ec29"><gtr:id>8daaabf2c4782bef479bb7d8bf61ec29</gtr:id><gtr:otherNames>Gupta N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a858aad59a602.72989898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6891024-9A1B-4642-B7BC-F4EE38F6FDB9</gtr:id><gtr:title>Risk factors for maternal anaemia and low birth weight in pregnant women living in rural India: a&amp;nbsp;prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f571642ba975fd15ef659c09162274f0"><gtr:id>f571642ba975fd15ef659c09162274f0</gtr:id><gtr:otherNames>Ahankari AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0033-3506</gtr:issn><gtr:outcomeId>5a858c2d24a635.69043385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52F0D125-4C3A-4044-8E9E-C49FCEA9C0FF</gtr:id><gtr:title>SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6d5b12a38ada177266136b89e274ba4"><gtr:id>c6d5b12a38ada177266136b89e274ba4</gtr:id><gtr:otherNames>Athwal VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5a858929480506.58873639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0918F44C-569D-478C-9BFC-606CE27B844C</gtr:id><gtr:title>Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease.</gtr:title><gtr:parentPublicationTitle>European journal of applied physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa75d5aa1d94062190e0150a6c00be5b"><gtr:id>aa75d5aa1d94062190e0150a6c00be5b</gtr:id><gtr:otherNames>Sargeant JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1439-6319</gtr:issn><gtr:outcomeId>5a8587efa4dcc5.91637836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43474057-A5C4-4A67-ABA2-8DA8F8CB6E4F</gtr:id><gtr:title>Frequency of stepping down antibiotics and nebuliser treatment is lower at weekends compared to weekdays: an observational study.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/941aead409448a3e4421f7c088cd3066"><gtr:id>941aead409448a3e4421f7c088cd3066</gtr:id><gtr:otherNames>Lewis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>5a858c2c81c9d8.41105010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D66FF259-294C-4903-AF3C-0C5488701497</gtr:id><gtr:title>Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abb6581228ad0251926a14bcffcc0a81"><gtr:id>abb6581228ad0251926a14bcffcc0a81</gtr:id><gtr:otherNames>Tanajewski L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a8587f1bac103.77008243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ED2384A-281C-49E7-9811-B94C8F480F2C</gtr:id><gtr:title>QMC-PCRx: a novel method for rapid mutation detection.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56347a58fef6daec35e63fd903d9e928"><gtr:id>56347a58fef6daec35e63fd903d9e928</gtr:id><gtr:otherNames>Ebili HO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>58bd94d905ca49.28572938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B171270D-9D50-4FB1-8B61-2DB4E1A600FB</gtr:id><gtr:title>Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment.</gtr:title><gtr:parentPublicationTitle>Open forum infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c0c59747c968916777f79112fe1de56"><gtr:id>2c0c59747c968916777f79112fe1de56</gtr:id><gtr:otherNames>Howes N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2328-8957</gtr:issn><gtr:outcomeId>5a85892c88cf79.68853558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>468644D7-985E-4AD5-9BD7-206130B88E6B</gtr:id><gtr:title>Drug-induced liver injury: recent advances in diagnosis and risk assessment.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/632973a0b7685dab184a4b7bfcbe19f1"><gtr:id>632973a0b7685dab184a4b7bfcbe19f1</gtr:id><gtr:otherNames>Kullak-Ublick GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5a8587f18235b6.56831167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B85F27E-A7BE-4FDC-9A81-1820622EC8C5</gtr:id><gtr:title>Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75f235afe3976f611342d0b14cd3bb2f"><gtr:id>75f235afe3976f611342d0b14cd3bb2f</gtr:id><gtr:otherNames>Walker AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>5a8589287cf0f7.48740583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A6CC2F0-B9F6-4F11-95E4-DCE4E3000457</gtr:id><gtr:title>Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017.</gtr:title><gtr:parentPublicationTitle>Endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfe2ee78b16374a1660a521e6f78b2e3"><gtr:id>bfe2ee78b16374a1660a521e6f78b2e3</gtr:id><gtr:otherNames>Polkowski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0013-726X</gtr:issn><gtr:outcomeId>5a8587f07372d7.49661649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60A139BC-6B61-4BD2-8FFC-C752C699D9EB</gtr:id><gtr:title>ECM Crosslinking Enhances Fibroblast Growth and Protects Against Matrix Proteolysis in Lung Fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/443fe50267234f5c6fbd419d91e020fa"><gtr:id>443fe50267234f5c6fbd419d91e020fa</gtr:id><gtr:otherNames>Philp CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>5a8589a2f39621.72020686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40D28AD9-ECF7-4457-927E-4CD3D9EBA691</gtr:id><gtr:title>Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd8a902aa068fd915081d291332da738"><gtr:id>dd8a902aa068fd915081d291332da738</gtr:id><gtr:otherNames>Aldajani WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58bd7ecd9c0c31.59893341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>763CA257-3C5E-4BA0-9768-CA9B003498FB</gtr:id><gtr:title>Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>5a858929d50060.50870734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0083EA46-26EC-4EF4-A544-D33578582340</gtr:id><gtr:title>An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f4736589f4d300b8fcd84212396e994"><gtr:id>0f4736589f4d300b8fcd84212396e994</gtr:id><gtr:otherNames>Jenkins RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>5a8589fda9fdd2.12037620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3883FF05-A2D0-4DE9-8316-84843B80CF4A</gtr:id><gtr:title>Helicobacter: Inflammation, immunology and vaccines.</gtr:title><gtr:parentPublicationTitle>Helicobacter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8daea59cb2444c40ecae21e2ae9d204b"><gtr:id>8daea59cb2444c40ecae21e2ae9d204b</gtr:id><gtr:otherNames>Robinson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1083-4389</gtr:issn><gtr:outcomeId>5a858c7c2a8c59.46257222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6149AF46-917A-4D0B-87E5-CDA2A3891195</gtr:id><gtr:title>Next-Generation Sequencing in Diagnostic Pathology.</gtr:title><gtr:parentPublicationTitle>Pathobiology : journal of immunopathology, molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ecdcc9a75efe61569ae89d2cdabfc84"><gtr:id>2ecdcc9a75efe61569ae89d2cdabfc84</gtr:id><gtr:otherNames>Ilyas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1015-2008</gtr:issn><gtr:outcomeId>5a858713599d92.14378420</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N005953/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>